Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average) (2012 - 2026)

Agios Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 15 years, with the latest figure at $58.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2.3% year-over-year to $58.8 million; the trailing twelve-month figure through Mar 2026 stood at $58.8 million (up 2.3% YoY), and the FY2025 full-year result was $58.0 million, up 2.05% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $58.8 million, up from $58.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $58.8 million in Q1 2026, with the low at $54.6 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $56.3 million across 5 years, with a median of $56.4 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) retreated 21.55% — and 2026, when it rose 2.3%.
• Agios Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $54.8 million in 2022, then rose by 1.57% to $55.7 million in 2023, then increased by 2.08% to $56.8 million in 2024, then grew by 2.05% to $58.0 million in 2025, then advanced by 1.4% to $58.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $58.8 million (Q1 2026), $58.0 million (Q4 2025), and $57.8 million (Q3 2025), per Business Quant data.